382 completed. 382 Phase 3, 44 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 382 | Completed 382 |
| Phase 2 | 44 | Completed 44 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD LPCN 1154A, Placebo - Depression, Postpartum, Depression, Post-Partum | Phase 3 | Completed | Lipocine Inc. | 90 | 2025-06-16 | 2026-02-24 |
| The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression Ammoxetine, Placebo, Sertraline - Major Depressive Disorder (MDD) | Phase 3 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 786 | 2025-02-21 | 2026-10-30 |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" CYB003, Psychological Support, Placebo - Major Depressive Disorder | Phase 3 | Completed | Cybin IRL Limited | 223 | 2024-12-17 | 2026-10-27 |
| Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder Levomilnacipran Hydrochloride Extended-Release Capsules, Duloxetine Hydrochloride Enteric Capsules - Major Depressive Disorder (MDD) | Phase 3 | Completed | Zhejiang Huahai Pharmaceutical Co., Ltd. | 392 | 2024-10-17 | 2025-11-28 |
| Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol Solriamfetol 300 mg, Placebo - Major Depressive Disorder | Phase 3 | Completed | Axsome Therapeutics, Inc. | 346 | 2024-03-18 | 2026-01-05 |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder NMRA-335140, Placebo - Major Depressive Disorder | Phase 3 | Completed | Neumora Therapeutics, Inc. | 422 | 2023-12-21 | 2026-07-06 |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder NMRA-335140, Placebo - Major Depressive Disorder | Phase 3 | Completed | Neumora Therapeutics, Inc. | 430 | 2023-12-20 | 2026-07-06 |
| Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder NMRA-335140, Placebo - Major Depressive Disorder | Phase 3 | Completed | Neumora Therapeutics, Inc. | 383 | 2023-09-20 | 2025-11-26 |
| OptimizeD Pilot Study Healthy Activity Program (HAP), Antidepressant medication (ADM) - Depression, Depressive Disorder | Phase 3 | Completed | Harvard Medical School (HMS and HSDM) | 76 | 2023-08-01 | 2024-04-09 |
| Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Psilocybin - Treatment Resistant Depression | Phase 3 | Completed | COMPASS Pathways | 258 | 2023-01-24 | 2026-08-10 |
| A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Completed | Janssen Research & Development, LLC | 444 | 2022-12-06 | 2026-02-13 |
| Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Celecoxib 400mg, Placebo - Depressive Disorder, Major, Inflammation | Phase 3 | Completed | Amsterdam UMC, location VUmc | 94 | 2022-09-28 | 2026-09-21 |
| Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25 Cramp Bites by Aunt Flo's Kitchen - Dysmenorrhea Primary, Dysmenorrhea | Phase 2 / Phase 3 | Completed | Cornell University | 12 | 2022-07-21 | 2024-04-12 |
| A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Completed | Janssen Research & Development, LLC | 513 | 2022-06-22 | 2025-11-06 |
| Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder Sertraline, Escitalopram - Major Depressive Disorder | Phase 3 | Completed | KRL Hospital, Islamabad | 744 | 2022-06-01 | 2023-07-18 |
| An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Lumateperone - Major Depressive Disorder | Phase 3 | Completed | Intra-Cellular Therapies, Inc. | 812 | 2021-10-08 | 2025-11-03 |
| Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Lumateperone, Placebo - Major Depressive Disorder | Phase 3 | Completed | Intra-Cellular Therapies, Inc. | 480 | 2021-09-30 | 2025-05-09 |
| Ketamine As an Adjunctive Therapy for Major Depression (2) Ketamine, Midazolam - Major Depressive Episode, Unipolar Depression | Phase 3 | Completed | University of Dublin, Trinity College | 63 | 2021-09-13 | 2025-02-13 |
| Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Lumateperone, Placebo - Major Depressive Disorder | Phase 3 | Completed | Intra-Cellular Therapies, Inc. | 485 | 2021-07-30 | 2025-05-02 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) REL-1017, Placebo - Major Depressive Disorder | Phase 3 | Completed | Relmada Therapeutics, Inc. | 232 | 2021-06-02 | 2024-03-26 |
Showing 20 of 382. Sign in to see all of them.
Depressive Disorder, Major (322) · Depression (160) · Depressive Disorder, Treatment-Resistant (22) · Mood Disorders (13) · Bipolar Disorder (12) · Depression, Postpartum (12) · Mental Disorders (12) · Psychotic Disorders (11) · Anxiety Disorders (8) · Sleep Initiation and Maintenance Disorders (6) · Dysthymic Disorder (5) · Recurrence (5) · Premenstrual Dysphoric Disorder (4) · Schizophrenia (4)
Mental Disorders (370) · Mood Disorders (369) · Behavior (163) · Behavioral Symptoms (160) · Pathological Conditions, Signs and Symptoms (23) · Nervous System Diseases (18) · Urogenital Diseases (17) · Pathologic Processes (15) · Female Urogenital Diseases and Pregnancy Complications (14) · Bipolar and Related Disorders (12) · Pregnancy Complications (12) · Puerperal Disorders (12) · Schizophrenia Spectrum and Other Psychotic Disorders (11) · Signs and Symptoms (11)
Escitalopram (33) · Duloxetine Hydrochloride (29) · Vortioxetine (29) · Fluoxetine (19) · Sertraline (19) · Antidepressive Agents (12) · Paroxetine (12) · Aripiprazole (10) · SR 48968 (10) · brexpiprazole (10) · Amibegron hydrochloride (9) · Aprepitant (9) · Esketamine (9) · Venlafaxine Hydrochloride (9) · Citalopram (8)
Eli Lilly and Company (21) · Sanofi (19) · Forest Laboratories (18) · Wyeth is now a wholly owned subsidiary of Pfizer (18) · H. Lundbeck A/S (17) · AstraZeneca (14) · Janssen Research & Development, LLC (13) · Otsuka Pharmaceutical Development & Commercialization, Inc. (13) · Takeda (13) · GlaxoSmithKline (12) · Merck Sharp & Dohme LLC (9) · Pfizer (9) · University Health Network, Toronto (7) · Alkermes, Inc. (6) · Biogen (6)
United States (232) · Canada (63) · Germany (46) · Poland (37) · France (35) · Bulgaria (29) · Finland (29) · Russia (28) · Slovakia (27) · Czechia (25) · Japan (25) · Mexico (25) · South Africa (25) · Spain (23) · Sweden (23)
Sanjeev Pathak, MD (6) · Carl Gommoll, MS (5) · Jenna Hoogerheyde (5) · Katherine Beebe, PhD (5)
PMID 25758058, PMID 24816198, PMID 26644956, PMID 26709542, PMID 29140227, PMID 34183490, PMID 24067192, PMID 24175720, PMID 26474010, PMID 24571916, PMID 27780334, PMID 31577867, PMID 31818787, PMID 34510411, PMID 34817851, PMID 36708956, PMID 23485955, PMID 23497790, PMID 26644957, PMID 27685842, PMID 30508090, PMID 32860422, PMID 34235612, PMID 37656180, PMID 39428602, PMID 21731833, PMID 22106941, PMID 23106023, PMID 23216998, PMID 23585997, PMID 23585999, PMID 23673347, PMID 24127687, PMID 24766999, PMID 27035159, PMID 29523415, PMID 33128208, PMID 34894307, PMID 35022754, PMID 37099968, PMID 38421922, PMID 38557430, PMID 40607746, PMID 40852147, PMID 41055581, PMID 16248986, PMID 18832427, PMID 20816039, PMID 22027845, PMID 23672772
2008 (10), 2014 (8), 2018 (3), 2015 (2), 2016 (2), 2019 (2), 2009 (1), 2017 (1), R01AT000001 (1), R01DA023190 (1), R01MD005905 (1), R01MH053735 (1), R01MH059708 (1), R01MH061331 (1), R01MH061410 (1)